Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Moderna stock dips 10% amid FDA resignation, signaling regulatory risks. Strong cash reserves can't offset competitive and ...

The company has already sent the FDA an application for a seasonal flu vaccine, but the agency will probably wait for upcoming data from an ongoing phase 3 study before it issues a decision. In ...

We recently published a list of Jim Cramer Discussed These 9 Stocks Recently. In this article, we are going to take a look at ...

Ward said it would be good to see data from studies of other variant vaccine boosters to compare to the Moderna combination. Expert advisors "must already be thinking about the population at risk ...

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), ...

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S.

Delving into the details, we found 40% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we ...

We recently published a list of 10 Stocks To Trade Without Tariffs And Interest Rate Fears. In this article, we are going to ...

The data Moderna has reported so far is encouraging, but it's probably best to wait for results from larger ongoing phase 3 studies before placing significant value on mRNA-4157. With the ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...

March 5 - Pfizer (PFE.N), opens new tab and BioNTech (22UAy.DE), opens new tab won a round in their legal battle with Moderna (MRNA.O), opens new tab over COVID-19 vaccine patents on Wednesday ...